With the market still wrestling with the reality that interest rates may stay higher for longer, let's dip back into the small-cap space and look for companies that are about to hit genuine inflection points.
We're seeing a lot of great development in the biotech space, especially as biopharmaceutical plays gear up to take on more complex cancers.
One company in particular, MorphoSys ( $MOR) has laid a strong foundation in their development of drugs that can take on a rare class of blood cancers. With new trial data set to hit the market before the end of the year, MorphoSys is about to prove they have a multi-year path to using one treatment to tackle a wide variety of cancers and disorders that stem from issues in bone marrow.
By focusing on treating a specific kind of cell (myeloid stem cells), MorphoSys now has the ability to significantly compound their returns as each new class of treatment moves through the clinical trial system.
This is the same broad sequence of wins that powered Novo Nordisk and Eli Lilly to outsized wins with their GLP-1 treatments that get at the root of dozens of different disorders.
So, let's take a quick look at the data coming out of MorphoSys and try to get a better understanding of how their results can push them toward a clinical breakthrough.👇